Michelle Greenman

5PUBLICATIONS
34CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersInnate immunityGlycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 14, 2026
A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

|Aug 27, 2025
Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.

Niccolò G Santin, Namrata Sethi, Stefania Bellone

|Apr 29, 2025
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.

Michelle Greenman, Cem Demirkiran, Stefania Bellone

|Apr 09, 2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).

Sangini S Sheth, Ji Eun Oh, Stefania Bellone

|Nov 14, 2023
Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.

Blair McNamara, Michelle Greenman, Nicole Pebley

Pageof 1

Frequent Collaborators

5 joint publications

Blair McNamara

5 joint publications

Alessandro D Santin

4 joint publications

Stefania Bellone

3 joint publications

Victoria M Ettorre